Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms--a retrospective feasibility study
Standard
Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms--a retrospective feasibility study. / Becker, Andreas; Placke, Anne ; Kluth, Luis; Schwarz, Rudolf; Isbarn, Hendrik; Chun, Felix; Heuer, Roman; Schlomm, Thorsten; Seiler, Daniel; Engel, Oliver; Fisch, Margit; Graefen, Markus; Ahyai, Sascha A.
in: J ENDOUROL, Jahrgang 28, Nr. 3, 01.03.2014, S. 335-41.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms--a retrospective feasibility study
AU - Becker, Andreas
AU - Placke, Anne
AU - Kluth, Luis
AU - Schwarz, Rudolf
AU - Isbarn, Hendrik
AU - Chun, Felix
AU - Heuer, Roman
AU - Schlomm, Thorsten
AU - Seiler, Daniel
AU - Engel, Oliver
AU - Fisch, Margit
AU - Graefen, Markus
AU - Ahyai, Sascha A
PY - 2014/3/1
Y1 - 2014/3/1
N2 - OBJECTIVE: To evaluate the outcome of holmium laser enucleation of the prostate (HoLEP) in the known presence of prostate cancer (PCa) and concomitant lower urinary tract symptoms (LUTS).PATIENTS AND METHODS: We retrospectively identified 62 patients who underwent HoLEP for LUTS in the known presence of PCa at our center. Perioperative data were assessed including complications, functional outcomes, and quality of life (QoL). Giving respect to different disease characteristics, patients were stratified according to treatment strategy setting into palliative (I), radiation (II), and surveillance (III) groups and compared accordingly.RESULTS: Median follow-up (FU) of the entire study cohort was 27 months (range 2-65 mos). Medians of functional parameters (International Prostate Symptom Score): 18.5 vs 4.5, QoL: 4 vs 1, maximal flow rate: 9.0 vs 18.8 mL/s and residual urine: 100 vs 0 mL, all P<0.05) improved significantly in all groups. Perioperative complications were low and without any statistically significant difference between the groups. Postoperatively, voiding was successful in 90.3% of all patients; at last FU, 17% had some degree of urinary incontinence. Treatment strategy groups showed comparable functional outcomes after HoLEP.CONCLUSION: In the presence of PCa and LUTS, HoLEP represents a feasible, safe, and effective treatment option for patients unfit or without indication for radical prostatectomy. This applies as well in a palliative situation of advanced, obstructive PCa as for patients with LUTS who are scheduled for radiation therapy or surveillance in presumably indolent disease.
AB - OBJECTIVE: To evaluate the outcome of holmium laser enucleation of the prostate (HoLEP) in the known presence of prostate cancer (PCa) and concomitant lower urinary tract symptoms (LUTS).PATIENTS AND METHODS: We retrospectively identified 62 patients who underwent HoLEP for LUTS in the known presence of PCa at our center. Perioperative data were assessed including complications, functional outcomes, and quality of life (QoL). Giving respect to different disease characteristics, patients were stratified according to treatment strategy setting into palliative (I), radiation (II), and surveillance (III) groups and compared accordingly.RESULTS: Median follow-up (FU) of the entire study cohort was 27 months (range 2-65 mos). Medians of functional parameters (International Prostate Symptom Score): 18.5 vs 4.5, QoL: 4 vs 1, maximal flow rate: 9.0 vs 18.8 mL/s and residual urine: 100 vs 0 mL, all P<0.05) improved significantly in all groups. Perioperative complications were low and without any statistically significant difference between the groups. Postoperatively, voiding was successful in 90.3% of all patients; at last FU, 17% had some degree of urinary incontinence. Treatment strategy groups showed comparable functional outcomes after HoLEP.CONCLUSION: In the presence of PCa and LUTS, HoLEP represents a feasible, safe, and effective treatment option for patients unfit or without indication for radical prostatectomy. This applies as well in a palliative situation of advanced, obstructive PCa as for patients with LUTS who are scheduled for radiation therapy or surveillance in presumably indolent disease.
KW - Aged
KW - Aged, 80 and over
KW - Feasibility Studies
KW - Follow-Up Studies
KW - Humans
KW - Laser Therapy
KW - Lasers, Solid-State
KW - Lower Urinary Tract Symptoms
KW - Male
KW - Middle Aged
KW - Prostatectomy
KW - Prostatic Neoplasms
KW - Quality of Life
KW - Retrospective Studies
KW - Treatment Outcome
KW - Urination
U2 - 10.1089/end.2013.0432
DO - 10.1089/end.2013.0432
M3 - SCORING: Journal article
C2 - 24147796
VL - 28
SP - 335
EP - 341
JO - J ENDOUROL
JF - J ENDOUROL
SN - 0892-7790
IS - 3
ER -